减肥和戒烟两个都要！司美格鲁肽助力患者“烟”消云散

Core Viewpoint - The study indicates that the GLP-1 receptor agonist semaglutide is associated with a significant reduction in healthcare encounters related to tobacco use disorders among patients with type 2 diabetes and obesity, suggesting its potential role in smoking cessation efforts [4][22]. Research Background - Tobacco use is linked to severe health issues, including cancer, cardiovascular diseases, and diabetes, with the WHO estimating over 8 million deaths annually due to smoking and secondhand smoke [6][8]. - In the U.S., nearly 12% of adults are current smokers, and the success rate for quitting smoking is low, with only 9.6% of adult smokers managing to quit in the past year [9]. Research Methodology - The study utilized electronic health records to simulate target trial analyses comparing semaglutide with seven other diabetes medications in improving healthcare indicators related to tobacco use disorders [10][13]. - A total of 222,942 new users of various diabetes medications were analyzed, including 5,967 users of semaglutide, over a one-year follow-up period [13]. Research Results - Semaglutide treatment was associated with a 12% to 32% reduction in healthcare visits due to tobacco use disorders compared to other diabetes medications [4][15]. - The risk of receiving prescriptions for smoking cessation medications was significantly lower for semaglutide users, with a hazard ratio (HR) of 0.32 compared to insulin [17]. - Semaglutide also showed a reduced risk of receiving smoking cessation counseling, with HRs ranging from 0.69 to 0.85 compared to other diabetes medications [17]. Mechanism Insights - GLP-1 receptor agonists, including semaglutide, may modulate the brain's reward and aversion systems, potentially reducing the rewarding effects of nicotine and enhancing aversion to smoking [18]. Research Limitations - The study acknowledges limitations such as potential record bias and lack of detailed data on smoking behavior, which may affect the reliability of conclusions regarding semaglutide's efficacy in smoking cessation [19][21]. Research Conclusion - Overall, semaglutide is linked to a significant reduction in healthcare encounters related to tobacco use disorders, indicating a potential decrease in smoking desire. However, further research and randomized clinical trials are necessary to confirm its application in smoking cessation [22].